GlassScriptPhysician profile
Wendy M Wilson
NPI 1427145986
$11,035.02
in general payments reported to CMS, 2019-2025
32 companies · $1,762 in 2025
The $1,762 reported for 2025 was more than what a typical Clinical & Laboratory Dermatological Immunology provider received nationally (typical 2025 total: $1,130).
See the full distribution for Clinical & Laboratory Dermatological Immunology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,543 · 2020: $1,131 · 2021: $1,453 · 2022: $1,668 · 2023: $1,859 · 2024: $1,619 · 2025: $1,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,145 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,144.55 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,744.91 | 2019-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $1,180.29 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $1,155.16 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $1,128.14 | 2019-2025 | Tremfya, Acclaim |
| Pfizer INC. | $1,088.51 | 2019-2025 | |
| Lilly USA, LLC | $856.61 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $776.80 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $526.21 | 2019-2025 | |
| Ucb, INC. | $484.87 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $399.85 | 2020-2025 | Adbry |
| Amgen INC. | $345.00 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $264.16 | 2019-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $191.85 | 2019-2025 | Nemluvio, Aklief |
| Hill Dermaceuticals, INC. | $129.68 | 2025 | Tolak |
| E.R. Squibb & Sons, L.L.C. | $95.81 | 2022-2024 | Sotyktu |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $77.96 | 2019-2025 | |
| Dermavant Sciences, INC. | $68.86 | 2022-2023 | Vtama |
| Almirall LLC | $67.93 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $62.67 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $61.58 | 2020-2021 | |
| Dermira, INC. | $44.42 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.83 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $38.78 | 2022 | |
| Convatec INC. | $31.88 | 2024 | |
| Aclaris Therapeutics, INC. | $31.37 | 2019 | |
| Prugen, INC. Pharmaceuticals | $28.74 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.17 | 2022 | |
| Sebela Pharmaceuticals INC. | $21.83 | 2021 | |
| Journey Medical Corporation | $19.42 | 2023 | |
| Verrica Pharmaceuticals INC. | $18.89 | 2023 | Ycanth |
| Biofrontera INC. | $18.46 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mission Pharmacal Company | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.